SCHEMBL14907124

SCHEMBL14907124

COc1ccc(Cl)cc1/C=N/NC(=O)c1cc(OC)c(O)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.61
MAPT P10636 3/20 0.61
LMNA P02545 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
GCGR P47871 1/20 0.59
ATM Q13315 1/20 0.58
PSMD14 O00487 2/20 0.57
DUSP3 P51452 1/20 0.57
PTPN5 P54829 1/20 0.57
PTPN11 Q06124 1/20 0.57
ALDH1A1 P00352 1/20 0.56
GAA P10253 1/20 0.56
CTDSP1 Q9GZU7 1/20 0.55
KDM1A O60341 1/20 0.54
HTT P42858 3/20 0.53
PTBP1 P26599 1/20 0.53
RECQL P46063 1/20 0.53
KMT2A Q03164 5/20 0.53
MEN1 O00255 4/20 0.53
PLA2G1B P04054 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14907037 0.95 GCGR (0.60) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14907022 0.92 ATM (0.57) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14907121 0.89 GCGR (0.64) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14906912 0.88 KDM1A (0.65) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14906901 0.88 GCGR (0.67) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14907117 0.87 MAPT (0.61) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14906946 0.86 KDM1A (0.61) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14907029 0.85 KDM4E (0.63) KDM4EMAPTLMNASMN1; SMN2GCGR
SCHEMBL14906908 0.85 GCGR (0.64) MAPTLMNASMN1; SMN2GCGRPSMD14
SCHEMBL12387818 0.85 MAPT (0.68) KDM4EMAPTLMNASMN1; SMN2GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873661-B2 Small molecule malarial Aldolase-TRAP enhancers and glideosome inhibitors NEW YORK UNIVERSITY (US) 2018-01-23 US disclosed
US-20140275088-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2014-09-18 US disclosed
WO-2013063243-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS NEW YORK UNIVERSITY (US) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275088-A1 SMALL MOLECULE MALARIAL ALDOLASE-TRAP ENHANCERS AND GLIDEOSOME INHIBITORS ALDOA, DERA, TALDO1 KDM4E 283/4885MAPT 578/4885LMNA 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.